vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and WESTAMERICA BANCORPORATION (WABC). Click either name above to swap in a different company.

WESTAMERICA BANCORPORATION is the larger business by last-quarter revenue ($63.3M vs $57.6M, roughly 1.1× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -9.0%). WESTAMERICA BANCORPORATION produced more free cash flow last quarter ($119.7M vs $-167.0M).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

Westamerica Bancorporation is a regional bank holding company headquartered in California, U.S. It operates via its wholly owned banking subsidiary to provide full-spectrum retail and commercial banking services, including deposit products, business and consumer loans, wealth management, and payment services, primarily serving individual consumers, SMEs and local institutional clients in northern and central California.

PHAT vs WABC — Head-to-Head

Bigger by revenue
WABC
WABC
1.1× larger
WABC
$63.3M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+103.1% gap
PHAT
94.1%
-9.0%
WABC
More free cash flow
WABC
WABC
$286.7M more FCF
WABC
$119.7M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PHAT
PHAT
WABC
WABC
Revenue
$57.6M
$63.3M
Net Profit
$27.8M
Gross Margin
86.7%
Operating Margin
59.8%
Net Margin
43.9%
Revenue YoY
94.1%
-9.0%
Net Profit YoY
71.6%
-12.3%
EPS (diluted)
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
WABC
WABC
Q4 25
$57.6M
$63.3M
Q3 25
$49.5M
$63.7M
Q2 25
$39.5M
$64.6M
Q1 25
$28.5M
$66.4M
Q4 24
$29.7M
$69.6M
Q3 24
$16.4M
$74.1M
Q2 24
$7.3M
$74.3M
Q1 24
$75.8M
Net Profit
PHAT
PHAT
WABC
WABC
Q4 25
$27.8M
Q3 25
$-30.0M
$28.3M
Q2 25
$-75.8M
$29.1M
Q1 25
$-94.3M
$31.0M
Q4 24
$31.7M
Q3 24
$-85.6M
$35.1M
Q2 24
$-91.4M
$35.5M
Q1 24
$36.4M
Gross Margin
PHAT
PHAT
WABC
WABC
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
PHAT
PHAT
WABC
WABC
Q4 25
59.8%
Q3 25
-30.8%
59.5%
Q2 25
-151.7%
60.5%
Q1 25
-276.5%
63.0%
Q4 24
62.8%
Q3 24
-433.0%
64.5%
Q2 24
-1055.4%
64.8%
Q1 24
65.2%
Net Margin
PHAT
PHAT
WABC
WABC
Q4 25
43.9%
Q3 25
-60.5%
44.3%
Q2 25
-191.9%
45.0%
Q1 25
-330.7%
46.7%
Q4 24
45.6%
Q3 24
-523.3%
47.3%
Q2 24
-1248.6%
47.8%
Q1 24
48.0%
EPS (diluted)
PHAT
PHAT
WABC
WABC
Q4 25
$1.12
Q3 25
$-0.41
$1.12
Q2 25
$-1.05
$1.12
Q1 25
$-1.31
$1.16
Q4 24
$1.19
Q3 24
$-1.32
$1.31
Q2 24
$-1.56
$1.33
Q1 24
$1.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
WABC
WABC
Cash + ST InvestmentsLiquidity on hand
$130.0M
Total DebtLower is stronger
$209.1M
Stockholders' EquityBook value
$-438.2M
$933.5M
Total Assets
$259.1M
$6.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
WABC
WABC
Q4 25
$130.0M
Q3 25
$135.2M
Q2 25
$149.6M
Q1 25
$212.3M
Q4 24
$297.3M
Q3 24
$334.7M
Q2 24
$276.2M
Q1 24
Total Debt
PHAT
PHAT
WABC
WABC
Q4 25
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
PHAT
PHAT
WABC
WABC
Q4 25
$-438.2M
$933.5M
Q3 25
$-422.5M
$931.6M
Q2 25
$-405.8M
$921.8M
Q1 25
$-338.4M
$923.1M
Q4 24
$-253.6M
$890.0M
Q3 24
$-187.1M
$909.0M
Q2 24
$-233.8M
$815.6M
Q1 24
$791.7M
Total Assets
PHAT
PHAT
WABC
WABC
Q4 25
$259.1M
$6.0B
Q3 25
$240.3M
$5.9B
Q2 25
$250.2M
$5.8B
Q1 25
$294.2M
$6.0B
Q4 24
$378.3M
$6.1B
Q3 24
$387.0M
$6.2B
Q2 24
$319.4M
$6.3B
Q1 24
$6.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
WABC
WABC
Operating Cash FlowLast quarter
$-166.8M
$121.9M
Free Cash FlowOCF − Capex
$-167.0M
$119.7M
FCF MarginFCF / Revenue
-290.0%
189.0%
Capex IntensityCapex / Revenue
0.4%
3.5%
Cash ConversionOCF / Net Profit
4.38×
TTM Free Cash FlowTrailing 4 quarters
$-328.9M
$213.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
WABC
WABC
Q4 25
$-166.8M
$121.9M
Q3 25
$-14.1M
$29.4M
Q2 25
$-62.7M
$23.5M
Q1 25
$-84.9M
$42.4M
Q4 24
$-266.8M
$141.6M
Q3 24
$-63.6M
$40.6M
Q2 24
$-70.7M
$19.0M
Q1 24
$52.2M
Free Cash Flow
PHAT
PHAT
WABC
WABC
Q4 25
$-167.0M
$119.7M
Q3 25
$-14.1M
$28.7M
Q2 25
$-62.8M
$22.8M
Q1 25
$-84.9M
$42.2M
Q4 24
$-266.9M
$139.8M
Q3 24
$-63.6M
$40.1M
Q2 24
$-70.8M
$18.6M
Q1 24
$52.1M
FCF Margin
PHAT
PHAT
WABC
WABC
Q4 25
-290.0%
189.0%
Q3 25
-28.6%
45.1%
Q2 25
-159.0%
35.3%
Q1 25
-297.9%
63.5%
Q4 24
-899.8%
201.0%
Q3 24
-389.0%
54.1%
Q2 24
-966.2%
25.0%
Q1 24
68.7%
Capex Intensity
PHAT
PHAT
WABC
WABC
Q4 25
0.4%
3.5%
Q3 25
0.1%
1.1%
Q2 25
0.2%
1.1%
Q1 25
0.1%
0.3%
Q4 24
0.5%
2.5%
Q3 24
0.3%
0.7%
Q2 24
0.6%
0.6%
Q1 24
0.2%
Cash Conversion
PHAT
PHAT
WABC
WABC
Q4 25
4.38×
Q3 25
1.04×
Q2 25
0.81×
Q1 25
1.37×
Q4 24
4.47×
Q3 24
1.16×
Q2 24
0.54×
Q1 24
1.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons